<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4700">
  <stage>Registered</stage>
  <submitdate>20/06/2014</submitdate>
  <approvaldate>20/06/2014</approvaldate>
  <nctid>NCT02172560</nctid>
  <trial_identification>
    <studytitle>A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler</studytitle>
    <scientifictitle>A Retrospective Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>205.392</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Disease, Chronic Obstructive</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tiotropium

Premature withdrawal from tiotropium - 


Treatment: drugs: Tiotropium


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number and status of patients dead or alive at the predicted end of treatment date</outcome>
      <timepoint>Until 48 weeks after first intake of randomised treatment + 30 days follow-up or date of death</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number and specification of patients on pulmonary medications and other pulmonary interventions</outcome>
      <timepoint>Until 48 weeks after first intake of randomised treatment + 30 days follow-up or date of death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients who withdrew prematurely from the randomised treatment phase of studies
             205.254 and 205.255.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>441</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Boehringer Ingelheim Investigational Site 61501 - Garran</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61403 - Clayton</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61502 - Adelaide</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61401 - Woodsville South</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61402 - Frankston</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61503 - Nedlands</hospital>
    <hospital>Boehringer Ingelheim Investigational Site 61405 - Perth</hospital>
    <postcode> - Garran</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Woodsville South</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otahuhu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Devon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Isleworth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Swansea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Torquay</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objectives were to collect information on vital status and pulmonary medication use at
      the predicted exit date for patients who participated in two one-year trials and withdrew
      prematurely. The primary objective was to ascertain the vital status (dead or alive) of these
      patients in the time interval between the patients' withdrawal from the trial and their
      predicted exit date (i.e: 48 weeks from first intake of randomised treatment + 30 days). The
      secondary objective was to collect information on classes of pulmonary medication and some
      other specified pulmonary interventions used by these prematurely discontinued patients at
      the time of their predicted exit date (i.e 48 weeks from the first intake of randomised
      treatment + 30 days) or at date of death (if this occurred during the time interval of
      interest, i.e 48 weeks from the first intake of randomised treatment + 30 days).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02172560</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>